Biotech Values

[DewDiligence]

>> Median survival was assesses in the iressa trial; it just wasn't a primary endpoint. <<

The Iressa trials in refractory NSCLC were not powered to detect a statically significant increase in median survival; rather, they were powered merely to detect a statistically significant increase in response rate (two-dimensional tumor shrinkage of 50%+ lasting at least one month).

At this point, we don’t’ know if Tarceva is a better drug than Iressa, or if Tarceva was merely the beneficiary of a better-designed clinical trial.